7:04AM Harvard Biosci announces receipt of private letter ruling and affirms plan to spin-off harvard apparatus regenerative technology following its IPO; HART has set a price range of $10.00 - $12.00 per share of common stock (HBIO) 5.74 : Co announced that it has received a private letter ruling from the Internal Revenue Service that subject to certain conditions, the anticipated spin-off of Harvard Apparatus Regenerative Technology, Inc. will be tax-free for U.S. federal income tax purposes. Harvard Apparatus Regenerative Technology, Inc., or HART, a wholly-owned subsidiary of Harvard Bioscience, has filed a registration statement with the SEC for an initial public offering of HART's common stock. HART has set a price range of $10.00 - $12.00 per share of common stock and has commenced its "road show". It is expected that the offering of HART's common stock will price in early April, with the offering closing shortly thereafter. With respect to the offering, Summer Street Research Partners is sole book-running manager, and Maxim Group LLC is co-lead manager.
Recent HBIO News
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/27/2026 11:30:21 AM
- Sidoti Events, LLC's May Micro-Cap Virtual Conference • ACCESS Newswire • 05/20/2026 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/12/2026 08:30:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:30:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:30:18 AM
- Harvard Bioscience Announces First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/12/2026 11:30:00 AM
- Harvard Bioscience to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2026 11:30:00 AM
- Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET • GlobeNewswire Inc. • 04/28/2026 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/21/2026 08:58:07 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/21/2026 08:56:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 01:57:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 01:44:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 01:48:04 PM
- Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 03/23/2026 12:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 06:13:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 11:31:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 09:56:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 11:30:12 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/13/2026 12:20:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 11:30:29 AM
- Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results • GlobeNewswire Inc. • 03/12/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 11:30:26 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 09:01:29 PM
- Harvard Bioscience Announces Reverse Stock Split • GlobeNewswire Inc. • 03/06/2026 09:01:00 PM
- Harvard Bioscience to Participate in KeyBanc’s Virtual Healthcare Forum • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM

